Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients

Jaya Pisupati, Ashok Jain, Gilbert Burckart, Imad Hamad, Sheila Zuckerman, John Fung, Raman Venkataramanan

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The authors evaluated the intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid after oral administration of mycophenolate mofetil in 10 liver transplant patients. Mycophenolic acid and its metabolite, mycophenolic acid glucuronide, were measured in plasma and urine by high-pressure liquid chromatography. The plasma protein binding of mycophenolic acid was determined by ultrafiltration. The maximum concentration of mycophenolic acid in plasma increased significantly (P ≤ .05) with time from 9.1 ± 7.2 μg/mL (<1 week) to 36.7 ± 15.6 μg/mL (1 month). The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 ± 42.1 μg•h/mL to 118.0 ± 57.6 μg•h/mL (P ≤.05). The plasma protein binding of mycophenolic acid increased from 92% to 98%, and the apparent oral clearance [CL/F] decreased from 32.9 ± 21.4 L/h during the first study period to 9.0 ± 4.4 L/h (P ≤ .05) during the third study period. The apparent intrinsic clearance of mycophenolic acid did not change significantly over time. The ratio of the area under the curve of mycophenolic acid glucluronide to mycophenolic acid in plasma decreased with time (25.5 ± 21.2 vs 8.0 ± 3.3) but did not reach statistical significance. The increased binding of mycophenolic acid to plasma proteins with time after transplantation appeared to contribute to the intraindividual variation, whereas differences in the ability of the liver to metabolize mycophenolic acid between patients appear to contribute to the large interindividual variation in the pharmacokinetics of mycophenolic acid. The observations in this study support the concept of measuring the unbound concentration of mycophenolic acid to optimize immunosuppressive drug therapy with mycophenolic acid.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalJournal of Clinical Pharmacology
Volume45
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Mycophenolic Acid
Pharmacokinetics
Transplants
Liver
Blood Proteins
Protein Binding
Ultrafiltration
Immunosuppressive Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pisupati, Jaya ; Jain, Ashok ; Burckart, Gilbert ; Hamad, Imad ; Zuckerman, Sheila ; Fung, John ; Venkataramanan, Raman. / Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. In: Journal of Clinical Pharmacology. 2005 ; Vol. 45, No. 1. pp. 34-41.
@article{ba3a51afce1a4240bc17941fcebd961a,
title = "Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients",
abstract = "The authors evaluated the intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid after oral administration of mycophenolate mofetil in 10 liver transplant patients. Mycophenolic acid and its metabolite, mycophenolic acid glucuronide, were measured in plasma and urine by high-pressure liquid chromatography. The plasma protein binding of mycophenolic acid was determined by ultrafiltration. The maximum concentration of mycophenolic acid in plasma increased significantly (P ≤ .05) with time from 9.1 ± 7.2 μg/mL (<1 week) to 36.7 ± 15.6 μg/mL (1 month). The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 ± 42.1 μg•h/mL to 118.0 ± 57.6 μg•h/mL (P ≤.05). The plasma protein binding of mycophenolic acid increased from 92{\%} to 98{\%}, and the apparent oral clearance [CL/F] decreased from 32.9 ± 21.4 L/h during the first study period to 9.0 ± 4.4 L/h (P ≤ .05) during the third study period. The apparent intrinsic clearance of mycophenolic acid did not change significantly over time. The ratio of the area under the curve of mycophenolic acid glucluronide to mycophenolic acid in plasma decreased with time (25.5 ± 21.2 vs 8.0 ± 3.3) but did not reach statistical significance. The increased binding of mycophenolic acid to plasma proteins with time after transplantation appeared to contribute to the intraindividual variation, whereas differences in the ability of the liver to metabolize mycophenolic acid between patients appear to contribute to the large interindividual variation in the pharmacokinetics of mycophenolic acid. The observations in this study support the concept of measuring the unbound concentration of mycophenolic acid to optimize immunosuppressive drug therapy with mycophenolic acid.",
author = "Jaya Pisupati and Ashok Jain and Gilbert Burckart and Imad Hamad and Sheila Zuckerman and John Fung and Raman Venkataramanan",
year = "2005",
month = "1",
day = "1",
doi = "10.1177/0091270004270145",
language = "English (US)",
volume = "45",
pages = "34--41",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. / Pisupati, Jaya; Jain, Ashok; Burckart, Gilbert; Hamad, Imad; Zuckerman, Sheila; Fung, John; Venkataramanan, Raman.

In: Journal of Clinical Pharmacology, Vol. 45, No. 1, 01.01.2005, p. 34-41.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients

AU - Pisupati, Jaya

AU - Jain, Ashok

AU - Burckart, Gilbert

AU - Hamad, Imad

AU - Zuckerman, Sheila

AU - Fung, John

AU - Venkataramanan, Raman

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The authors evaluated the intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid after oral administration of mycophenolate mofetil in 10 liver transplant patients. Mycophenolic acid and its metabolite, mycophenolic acid glucuronide, were measured in plasma and urine by high-pressure liquid chromatography. The plasma protein binding of mycophenolic acid was determined by ultrafiltration. The maximum concentration of mycophenolic acid in plasma increased significantly (P ≤ .05) with time from 9.1 ± 7.2 μg/mL (<1 week) to 36.7 ± 15.6 μg/mL (1 month). The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 ± 42.1 μg•h/mL to 118.0 ± 57.6 μg•h/mL (P ≤.05). The plasma protein binding of mycophenolic acid increased from 92% to 98%, and the apparent oral clearance [CL/F] decreased from 32.9 ± 21.4 L/h during the first study period to 9.0 ± 4.4 L/h (P ≤ .05) during the third study period. The apparent intrinsic clearance of mycophenolic acid did not change significantly over time. The ratio of the area under the curve of mycophenolic acid glucluronide to mycophenolic acid in plasma decreased with time (25.5 ± 21.2 vs 8.0 ± 3.3) but did not reach statistical significance. The increased binding of mycophenolic acid to plasma proteins with time after transplantation appeared to contribute to the intraindividual variation, whereas differences in the ability of the liver to metabolize mycophenolic acid between patients appear to contribute to the large interindividual variation in the pharmacokinetics of mycophenolic acid. The observations in this study support the concept of measuring the unbound concentration of mycophenolic acid to optimize immunosuppressive drug therapy with mycophenolic acid.

AB - The authors evaluated the intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid after oral administration of mycophenolate mofetil in 10 liver transplant patients. Mycophenolic acid and its metabolite, mycophenolic acid glucuronide, were measured in plasma and urine by high-pressure liquid chromatography. The plasma protein binding of mycophenolic acid was determined by ultrafiltration. The maximum concentration of mycophenolic acid in plasma increased significantly (P ≤ .05) with time from 9.1 ± 7.2 μg/mL (<1 week) to 36.7 ± 15.6 μg/mL (1 month). The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 ± 42.1 μg•h/mL to 118.0 ± 57.6 μg•h/mL (P ≤.05). The plasma protein binding of mycophenolic acid increased from 92% to 98%, and the apparent oral clearance [CL/F] decreased from 32.9 ± 21.4 L/h during the first study period to 9.0 ± 4.4 L/h (P ≤ .05) during the third study period. The apparent intrinsic clearance of mycophenolic acid did not change significantly over time. The ratio of the area under the curve of mycophenolic acid glucluronide to mycophenolic acid in plasma decreased with time (25.5 ± 21.2 vs 8.0 ± 3.3) but did not reach statistical significance. The increased binding of mycophenolic acid to plasma proteins with time after transplantation appeared to contribute to the intraindividual variation, whereas differences in the ability of the liver to metabolize mycophenolic acid between patients appear to contribute to the large interindividual variation in the pharmacokinetics of mycophenolic acid. The observations in this study support the concept of measuring the unbound concentration of mycophenolic acid to optimize immunosuppressive drug therapy with mycophenolic acid.

UR - http://www.scopus.com/inward/record.url?scp=16644381286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644381286&partnerID=8YFLogxK

U2 - 10.1177/0091270004270145

DO - 10.1177/0091270004270145

M3 - Article

C2 - 15601803

AN - SCOPUS:16644381286

VL - 45

SP - 34

EP - 41

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -